Compare Ascendis Pharma A/S (ASND) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs McCormick & Company, Incorporated — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while McCormick & Company, Incorporated trades at $52.45 (market cap $14.08B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 3.66% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MKC | |
|---|---|---|
Market Cap | $17.74B | $14.08B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $72.81 |
52-Week Low | $163.32 | $45.60 |
Enterprise Value | $18.11B | $18.68B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
McCormick (MKC) trades at $52.45, up 1.77% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 21.91% net income margin and 25.7% ROE, supported by a transformative $45 billion Unilever Foods deal announced in July 2026. Valuation appears attractive with a P/E of 8.73, below industry averages, while cash flow trends indicate robust operational performance.
The outlook is mixed; analyst consensus targets $59.67 (14% upside) with a 'Hold' bias, but weak consumer volume growth and integration risks from the Unilever acquisition pose challenges. The stock offers a near 4% dividend yield, providing income support, yet execution on cost savings and volume recovery remains critical for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
